venBio Partners
Latest statistics and disclosures from venBio Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Apellis Pharmaceuticals, VRNA, Menlo Therapeutics, and represent 100.00% of venBio Partners's stock portfolio.
- venBio Partners has $38M in assets under management (AUM), dropping by -33.40%.
- Central Index Key (CIK): 0001737053
Tip: Access up to 7 years of quarterly data
Positions held by venBio Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for venBio Partners
venBio Partners holds 3 positions in its portfolio as reported in the December 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals | 62.0 | $24M | 1.8M | 13.19 |
|
|
| Verona Pharma Plc ads (VRNA) | 22.2 | $8.4M | 875k | 9.65 |
|
|
| Menlo Therapeutics | 15.8 | $6.0M | 1.5M | 4.12 |
|
Past Filings by venBio Partners
SEC 13F filings are viewable for venBio Partners going back to 2018
- venBio Partners 2018 Q4 filed Feb. 14, 2019
- venBio Partners 2018 Q3 filed Nov. 14, 2018
- venBio Partners 2018 Q2 filed Aug. 14, 2018
- venBio Partners 2017 Q4 filed April 25, 2018
- venBio Partners 2018 Q1 filed April 25, 2018